UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ______________. Commission file number: 001-38241 OPTINOSE, INC. (Exact name of registrant as specified in its charter) (State of other jurisd ...

OptiNose, Inc. (NASDAQ:OPTN) Q2 2020 Earnings Conference Call August 4, 2020 8:00 AM ET Company Participants Jonathan Neely - Vice President, Investor Relations Peter Miller - Chief Executive Officer Ramy Mahmoud - President and Chief Operating Officer Vic Clavelli - Chief Commercial Officer Keith Goldan - Chief Financial Officer Conference Call Participants Rafay Sardar - BMO Capital Markets Brandon Folkes - Cantor Fitzgerald Stacy Ku - Cowen Randall Stanicky - RBC Capital Markets David Amsellem - Piper Sa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ______________. Commission file number: 001-38241 OPTINOSE, INC. (Exact name of registrant as specified in its charter) Delaware 42-1771610 (State ...

OptiNose, Inc. (NASDAQ:OPTN) Q1 2020 Earnings Conference Call May 7, 2020 4:15 PM ET Company Participants Jonathan Neely - Vice President of Investor Relations Peter Miller - Chief Executive Officer Keith Goldan - Chief Financial Officer Vic Clavelli - Chief Commercial Officer Conference Call Participants Ken Cacciatore - Cowen & Company David Amsellem - Piper Sandler David Steinberg - Jefferies Operator Ladies and gentlemen, thank you for standing by and welcome to the OptiNose Q1 2020 Earnings Call. At th ...

| --- | --- | --- | --- | |-------|-------------------|----------------------------------|-------| | | | | | | | Specialty Company | Building a Leading ENT / Allergy | | | | | Corporate Presentation | | | | | May 7, 2020 | | Forward-Looking Statements This presentation and our accompanying remarks contain "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statement ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ______________. Commission file number: 001-38241 OPTINOSE, INC. (Exact name of registrant as specified in its charter) Delaware 42-1771610 (State ...

Optinose, Inc. (NASDAQ:OPTN) Q4 2019 Earnings Conference Call March 5, 2020 7:30 AM ET Company Participants Jonathan Neely - Vice President of Investor Relations Peter Miller - Chief Executive Officer Ramy Mahmoud - President & Chief Operating Officer Vic Clavelli - Chief Commercial Officer Keith Goldan - Chief Financial Officer Conference Call Participants Gary Nachman - BMO Capital Markets Ken Cacciatore - Cowen and Company David Amsellem - Piper Sandler Brandon Folkes - Cantor Fitzgerald David Steinberg ...

| --- | --- | --- | |-------|-----------------------------------------------------|-------| | | | | | | Building a Leading ENT / Allergy Specialty Company | | | | Corporate Presentation | | | | | | | | March 5, 2020 | | Forward-Looking Statements This presentation and our accompanying remarks contain "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2019 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ___________ to ______________. Commission file number: 001-38241 OPTINOSE, INC. (Exact name of registrant as specified in its charter) Delaware 42-1771610 (State of other jur ...

Optinose, Inc. (NASDAQ:OPTN) Q3 2019 Results Earnings Conference Call November 12, 2019 4:30 PM ET Company Participants Jonathan Neely - Vice President, Investor Relations Peter Miller - Chief Executive Officer Ramy Mahmoud - President and COO Keith Goldan - Chief Financial Officer Conference Call Participants Gary Nachman - BMO Capital Markets David Steinberg - Jefferies David Amsellem - Piper Jaffray Randall Stanicky - RBC Capital Markets Operator Ladies and gentlemen, thank you for standing by. And welco ...